Clinical Trial Update: Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study update for DSB2455 assessing safety, tolerability, and activity in advanced HRD-associated cancers, including breast cancer, ovarian cancer, metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer
• Castration-resistant Prostate Cancer
• Ovarian Cancer

Drugs mentioned

• DSB2455

Snippet

Sponsor: Duke Street Bio Ltd | Conditions: Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases) | Phase 1 | Status: RECRUITING